Open AccessID:4007 Immune-cell base for cancer therapy
Author(s) -
Van Thanh Ta,
Thinh Huy Tran,
Binh Thanh Nguyen,
Linh V. Nguyen,
Hoai Quy Nguyen,
Khanh V. Tran
Publication year - 2017
Publication title -
biomedical research and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 1
ISSN - 2198-4093
DOI - 10.15419/bmrat.v4is.217
Subject(s) - cytotoxic t cell , ctl* , cd28 , adoptive cell transfer , cd8 , immunology , immune system , t cell , major histocompatibility complex , granzyme , t cell receptor , biology , granzyme b , cell therapy , fas ligand , cancer research , tumor necrosis factor alpha , perforin , microbiology and biotechnology , apoptosis , programmed cell death , stem cell , biochemistry , in vitro
The development of immune cell-based approaches for treatment of cancer has been actively investigated for many years. One strategy that has been demonstrated as an effective method for cancer treatment is adoptive T cell therapy. The principle of this method is using Cytotoxic T lymphocytes (CTL), a crucial component of the adaptive immune system that aids in the control of intracellular pathogens. Effector CTL have the capacity to promote the apoptotic death of specifically targeted cells, using a combination of granule (perforin/granzyme)-and receptor (Fas/tumor necrosis factor)-mediated mechanisms. CTL recognize specific antigen on target cells using an unique T-cell receptor (TCR) when they are presented by class I major histocompatibility (MHC) molecules. In this study, we demonstrated that T lymphocytes were activated and dramatically expanded by stimulation with anti-CD3/CD28 antibodies and culture in the present of IL-2, IL-15 and IL-21 cytokines. These T cells exhibited a predominantly activated phenotype as manifested by an increase in the percentage of cells expressing CD8 and generation of various cytokines such as IL-2, INFγ and TNFa. These findings indicate that stimulation by anti- CD3/CD28 generated effector CTL in adoptive T-cell therapy for cancer.